Table 4 Subgroup analysis of OS in mPVTT patients treated with DEB-TACE or C-TACE
Factors | Median OS in DEB-TACE (Months) | Median OS in C-TACE (Months) | P-Value |
|---|---|---|---|
Child–Pugh | |||
 A | 13.0 (11.5–14.5) | 4.0 (3.0–5.0) |  < 0.001 |
 B | 9.0 (2.8–15.2) | 10.0 (4.4–15.6) | 0.997 |
AFP value | |||
 ≤ 400 ng/ml | 14.0 (8.9–19.1) | 8.0 (3.9–12.1) | 0.033 |
 > 400 ng/ml | 12.0 (5.2–18.8) | 4.0 (2.5–5.5) | 0.001 |
APS | |||
 Present | 5.0 (3.0–7.0) | 3.0 (2.1–3.9) | 0.040 |
 Absent | 14.0 (11.4–16.6) | 9.0 (5.7–12.3) | 0.001 |
HVI | |||
 Present | 12.0 (5.7–18.3) | 4.0 (3.0–5.0) | 0.003 |
 Absent | 13.0 (9.1–16.9) | 9.0 (4.8–13.2) | 0.058 |
EHS | |||
 Present | 12.0 (4.1–19.6) | 4.0 (3.1–4.9) | 0.016 |
 Absent | 12.0 (8.0–16.0) | 6.0 (3.1–8.9) | 0.007 |
Maximum Diameter | |||
 ≤ 5 cm | 14.0 (12.0–16.0) | 12.0 (2.6–21.4) | 0.254 |
 > 5 cm | 12.0 (6.4–17.6) | 5.0 (3.9–6.1) |  < 0.001 |
Capsular Infiltration | |||
 Non-infiltration | 18.0 (8.2–27.8) | 9.0 (3.8–14.2) | 0.001 |
 Infiltration | 8.0 (4.2–11.8) | 4.0 (2.4–5.6) | 0.012 |
Tumor Numbers | |||
 Single | 14.0 (1.0–27.0) | 4.0 (2.5–5.5) | 0.668 |
 Multiple | 12.0 (7.5–16.5) | 5.0 (2.8–7.2) |  < 0.001 |
Tumor Response | |||
 CR + PR + SD | 14.0 (12.2–15.8) | 9.0 (6.3–11.7) | 0.001 |
 PD | 4.0 (3.1–4.9) | 4.0 (3.4–4.6) | 0.590 |